Oral Semaglutide + Basal Insulin
Jul 18, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Lawand Kamal, PharmD Candidate 2021, Skaggs School of Pharmacy and Pharmaceutical Sciences
Analysis of the PIONEER 8 trial reveals dose-dependent reductions in A1c and body weight when oral semaglutide is paired with various insulin regimens.
Massive amounts of research and studies have been conducted to evaluate the various aspects of oral semaglutide as the first oral glucagon-like peptide-1 (GLP-1) receptor agonist. One of the most massive sets of trials investigating oral semaglutide is the "Peptide Innovation for Early Diabetes Treatment (PIONEER)" trials. Currently, there are a total of ten PIONEER trials that have been completed, with even more trials in this series that are currently in progress. The PIONEER 8 trial was designed to explore the safety, efficacy, and tolerability of oral semaglutide when added to an insulin regimen with or without metformin....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.